Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome

American Heart Journal

Volumn 154, Issue 4, 2007, Pages 624-631

  Lacro, Ronald V ^a   Dietz, Harry C ^b   Wruck, Lisa M ^c   Bradley, Timothy J ^d   Colan, Steven D ^a,c   Devereux, Richard B ^e   Klein, Gloria L ^c   Li, Jennifer S ^f   Minich, L LuAnn ^g   Paridon, Stephen M ^h   Pearson, Gail D ⁱ   Printz, Beth F ^j   Pyeritz, Reed E ^k   Radojewski, Elizabeth ^d   Roman, Mary J ^e   Saul, J Philip ^l   Stylianou, Mario P ⁱ   Mahony, Lynn ^m  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^j NewYork Presbyterian Hospital   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^m UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; LOSARTAN; PLACEBO; PROPRANOLOL;

AORTA DISSECTION; AORTA ROOT; AORTA SURGERY; AORTA VALVE REGURGITATION; ARTICLE; BODY GROWTH; BODY SURFACE; BONE GROWTH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEATH; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE; HUMAN; INCIDENCE; MARFAN SYNDROME; METHODOLOGY; MITRAL VALVE REGURGITATION; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATENOLOL; HUMANS; LOSARTAN; MARFAN SYNDROME; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN;

EID: 34548775221     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.06.024     Document Type: Article

References (35)

1. Judge D.P., and Dietz H.C. Marfan's syndrome. Lancet 366 (2005) 1965-1976
2. Silverman D.I., Burton K.J., Gray J., et al. Life expectancy in the Marfan syndrome. Am J Cardiol 75 (1995) 157-160
3. Pyeritz R.E. Marfan syndrome: current and future clinical and genetic management of cardiovascular manifestations. Semin Thorac Cardiovasc Surg 5 (1993) 11-16
4. Gott V.L., Greene P.S., Alejo D.E., et al. Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med 340 (1999) 1307-1313
5. Dietz H.C., Cutting G.R., Pyeritz R.E., et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352 (1991) 337-339
6. Collod-Beroud G., Beroud C., Ades L., et al. Marfan database (third edition): new mutations and new routines for the software. Nucleic Acids Res 26 (1998) 229-233
7. Visconti R.P., Barth J.L., Keeley F.W., et al. Codistribution analysis of elastin and related fibrillar proteins in early vertebrate development. Matrix Biol 22 (2003) 109-121
8. Sakai L.Y., Keene D.R., Glanville R.W., et al. Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. J Biol Chem 266 (1991) 14763-14770
9. Munger J.S., Harpel J.G., Gleizes P.E., et al. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int 51 (1997) 1376-1382
10. Bonewald L.F. Regulation and regulatory activities of transforming growth factor beta. Crit Rev Eukaryot Gene Expr 9 (1999) 33-44
11. Isogai Z., Ono R.N., Ushiro S., et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 278 (2003) 2750-2757
12. Dallas S.L., Keene D.R., Bruder S.P., et al. Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo. J Bone Miner Res 15 (2000) 68-81
13. Neptune E.R., Frischmeyer P.A., Arking D.E., et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33 (2003) 407-411
14. Loeys B.L., Chen J., Neptune E.R., et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 37 (2005) 275-281
15. Ng C.M., Cheng A., Myers L.A., et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 114 (2004) 1586-1592
16. Habashi J.P., Judge D.P., Holm T.M., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312 (2006) 117-121
17. Shores J., Berger K.R., Murphy E.A., et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 330 (1994) 1335-1341
18. Rossi-Foulkes R., Roman M.J., Rosen S.E., et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 83 (1999) 1364-1368
19. Salim M.A., Alpert B.S., Ward J.C., et al. Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol 74 (1994) 629-633
20. Selamet Tierney E.S., Feingold B., Printz B.F., et al. Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr 150 (2007) 77-82
21. Yetman A.T., Bornemeier R.A., and McCrindle B.W. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 95 (2005) 1125-1127
22. Dean J.C. Management of Marfan syndrome. Heart 88 (2002) 97-103
23. Nagashima H., Sakomura Y., Aoka Y., et al. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation 104 (2001) I282-I287
24. Mahony L., Sleeper L.A., Anderson P.A., et al. The Pediatric Heart Network: a primer for the conduct of multicenter studies in children with congenital and acquired heart disease. Pediatr Cardiol 27 (2006) 191-198
25. de Paepe A., Devereux R.B., Dietz H.C., et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 62 (1996) 417-426
26. Greally, MT. Shprintzen-Goldberg syndrome. GeneReviews at GeneTests: Medical Genetics Information Resource (database online). 1-13-2006. University of Washington, Seattle. 1997-2006. 3-29-2006.
27. Erkula G., Jones K.B., Sponseller P.D., et al. Growth and maturation in Marfan syndrome. Am J Med Genet 109 (2002) 100-115
28. Amery A., De Plaen J.F., Lijnen P., et al. Relationship between blood level of atenolol and pharmacologic effect. Clin Pharmacol Ther 21 (1977) 691-699
29. Tuininga Y.S., Crijns H.J., Brouwer J., et al. Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients. Circulation 92 (1995) 3415-3423
30. Davies R.R., Goldstein L.J., Coady M.A., et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 73 (2002) 17-27
31. Nollen G.J., Groenink M., Tijssen J.G., et al. Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome. Eur Heart J 25 (2004) 1146-1152
32. Davies R.R., Gallo A., Coady M.A., et al. Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg 81 (2006) 169-177
33. Fitzmaurice G.M., Laird N.M., and Ware J.H. Applied longitudinal analysis (2004), John Wiley & Sons, Inc, Hoboken (NJ)
34. O'Brien P.C., and Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556.
35. Lan K.K.G., and Demets D.L. Discrete sequential boundaries for clinical trials. Biometrika 70 (1983) 659-663